Key Takeaways
- Guidance trimmed on Unichem drag: Consolidated EBITDA margin expansion is now guided at ~75 bps (vs 100 bps earlier) and Unichem EBITDA growth for FY26 is ruled out, both because of a weak Q1.
- Domestic formulation engine intact but idling lower: Domestic business grew ~10%, still above market, but slowed by a cardiovascular division reorganization that disrupted product-to-people alignment and delayed manpower recruitment.
- Export growth broad-based, UK a notable exception: Branded formulations, generics and API all grew double digits, led by Europe and Latin America, while the UK market suffered from excess inventory and below-cost selling.
- US story is early-stage and two-speed: Ipca has begun shipping its own products and sees a path to $15–$16 mn annualised from current wins, but Unichem lost share on profitable US products and recovery is still a hope.
- What to watch next quarter: Whether the cardiovascular division stabilises and returns to faster growth, any sign of Unichem regaining lost US share, and the pace of Ipca’s own US product launches.
Domestic Formulation: The Cardiac Disruption
- Cardiovascular therapy slowdown: Grew only ~8% after two new marketing divisions were added, causing temporary disruption from product-to-people shifts and delays in recruiting the ~400 additional manpower needed.
- Recovery underway: Management stated faster recovery is happening and it is hopeful of doing much better than before in cardiovascular therapies once the new divisions settle.
- Market share still improved: Ipca improved overall market share by ~7 bps YoY to 2.08% in mid-June 2025, with both acute and chronic segments delivering better growth than the market despite the cardiac drag.
- Field force expansion continues: Around 3%–4% field additions every year, tilted toward specialty segments (Derma, Urology, CNS); cardiac recently added so not much further addition there.
- Margin trajectory tied to headcount discipline: Standalone margins expanded 1.5% in Q1 and the trend is expected to continue, provided the company does not add too many people, because productivity keeps building up.
A. K. Jain: "If you don't add too many people, margins will definitely keep on expanding because your productivity keeps on building up."
Unichem: The Consolidated Margin Anchor
- Q1 was a collection of one-offs and competitive losses: Unichem's quarter was hit by loss of market share on 2–3 profitable US products where it had its own API and good margin, a decline in high-margin Asia business (Myanmar import license issues), Brazil business decline, a ~₹12 cr additional currency fluctuation provision on a European Competition Commission provision, and ~₹10 cr expenditure from the Ireland facility closure announcement.
- US competitive pressure: Unichem lost business to competition on those 2–3 products; it has gained market share in other products but that business has yet to materialise.
- UK was a bright spot for Unichem: Some of Unichem's products had a shortage in the UK market, which drove its European business growth in the quarter, even as Ipca's own UK business struggled.
- Ireland facility closure: A ~₹10 cr provision was made in Unichem's books following the announcement of the Ireland facility closure; the facility is being shut down.
- Full-year EBITDA growth ruled out: Management explicitly stated that Unichem EBITDA growth for FY26 is not possible because of what happened in Q1, though the next three quarters should do better than Q1.
- Synergy benefits still a year away: Filing products in various markets is underway, but once registration starts, marketing will initiate; synergy benefits will still take around one year.
Harish Kamath: "What happened, 2-3 products where they were having very good market share and their own API and good margin, they lost business to some competition. So, they have gained market share in other products, but that business has yet to come."
US Business: Early Innings, Two Engines
- Ipca has started shipping its own products to the US: One US filing happened in Q1, and ~15–16 products are under various stages of development; another 4–5 products should get launched during the current financial year, with 5–6 Ipca products expected to launch every year thereafter.
- Current wins point to $15–$16 mn annualised: Management stated that deal wins already secured could translate to ~$15–$16 million in annual business, with more deals expected to be won in the remaining three quarters.
- Ipca–Unichem profit-sharing model: Ipca's US business with Unichem operates on a profit-sharing basis: a certain percentage goes to Unichem as selling and distribution cost, and the remaining profit is shared between Ipca and Unichem; no additional people are required for Ipca's US business.
- Unichem's US recovery is a hope, not a commitment: Management is hopeful that recovery will happen in coming quarters on the products where market share was lost in Q1, but no timeline or quantification was offered.
- No overall US sales figure disclosed: Per an analyst's math, management was asked for overall US sales including Unichem for the quarter but did not provide the figure, instead discussing deal wins and recovery expectations.
Export Markets: UK Pain, Rest of World Gain
- Branded formulations grew 10%, generics grew 15%, API grew 12%: Export growth was driven particularly by Europe and Latin America, offsetting some decline in domestic API.
- UK market was exceptionally tough: Excess inventory, players offloading short-dated expiries, and product prices coming down meant some products were selling below cost; sales prices in the UK were lower than what was shipped from India.
- UK ambition remains large: Management expects much greater business, maybe more than ₹300 crores in the UK in time to come, as products in the pipeline mature and get registration.
- Canada, Australia, New Zealand surged: Significant shipment in Q1, possibly exceeding 100% growth, with better margins.
- API pricing stable: API pricing is positively stable, not in a downtrend, with demand gradually improving in the export market; 2–3 new API products come into the market every year.
A. K. Jain: "some of the products were even selling below cost. What has been shipped from India, the sales prices in UK was lower than that."
Subsidiaries & Projects: Investment Phase Continues
- Pisgah injectable project: Ongoing and should get commercially ready by the second half of this financial year; post-commercialisation, some improvement can be seen, but the initial period may incur losses and a 2-year period is a good number to see scaling up.
- Onyx Scientific struggling: Multinational companies are reducing non-necessary expenses, so project-based business has reduced; Onyx had been making consistent profits for the last decade but this year the situation is difficult and no change in trend is visible yet.
- Germany subsidiary being set up: Registration of the company is being initiated; for some time it may incur losses, with a 1–2 year journey of initial losses before building up the business.
- Dewas facility progressing: A regulatory inspection has been done by one agency and others are expected; dossier filings have started from Dewas and export business to some markets has already commenced.
- Institutional sales stagnant: Same as last year Q1, mostly due to funding constraints; no growth is expected this year.
A. K. Jain: "I think 2-3 years period is a good, 2 years period is a good number to see that. We scale up all these kind of subsidiaries."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated topline growth | 9%–10% growth | FY26 full year |
| Consolidated EBITDA margin expansion | ~75 bps increase (revised from 100 bps) | FY26 full year |
| Standalone EBITDA margin expansion | 1.5% increase in Q1; trend to continue | FY26 full year |
| Unichem EBITDA growth | Not possible for FY26 because of Q1 | FY26 full year |
| Ipca US product launches | 4–5 more products launched | FY26 (current financial year) |
| Ipca US annual launch cadence | 5–6 products every year | Ongoing from FY26 |
| Pisgah injectable commercial readiness | Commercially ready | H2 FY26 |
| Unichem synergy benefits materialise | Around one year from now | ~FY27 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Standalone revenue | Not explicitly stated as a single figure; domestic business grew ~10% YoY |
| Consolidated revenue growth guidance | 9%–10% for FY26 |
| Standalone EBITDA margin | 23.82%, up from 22.22% in Q1 FY25 |
| Consolidated EBITDA margin | ~18.39%, down from 18.52% in Q1 FY25 |
| Consolidated EBITDA margin guidance | ~75 bps improvement for FY26, revised from 100 bps |
| Standalone net profit | ~₹262 cr, up ~26% YoY |
| Consolidated net profit | ~₹234 cr, up ~18% YoY |
| Standalone gross margin | ~74% |
| Domestic formulation growth (IQVIA) | 11.6%, vs IPM growth of ~8% |
| Acute segment growth (IQVIA) | 9.8%, vs industry acute growth of 6.8% |
| Chronic segment growth (IQVIA) | 15.1%, vs industry chronic growth of ~9.9% |
| Branded formulation exports | ~₹124 cr, up 10% YoY from ~₹113 cr |
| Generic exports | ~₹326 cr, up ~15% YoY from ₹283 cr |
| API business growth | ~12% YoY |
| Unichem consolidated revenue growth | ~9% YoY |
| Unichem US business growth | ~12% YoY |
| Ipca standalone US business annual run-rate visibility | $15–$16 million for FY26 |
| Overall market share (IQVIA, mid-June 2025) | 2.08%, up ~7 bps from 2.01% in mid-June 2024 |
| Cardiovascular therapy growth | ~8% in Q1 |
| Pain management therapy growth | ~13% in Q1 |
| MR additions in cardiovascular | ~400 people added |
| Total salesforce | Just over 7,000 people |
| Onyx Scientific Q1 loss | ~£300,000 |
| Unichem additional provision (currency fluctuation on EU penalty) | ~₹12 cr |
| Unichem Ireland facility closure redundancy cost | ~₹8–₹10 cr |
| Unichem Asia business (Myanmar impact) | Declined from ₹23 cr to ~₹8 cr |
| Unichem Brazil business | Declined from ₹21 cr to ~₹14 cr |
| Unichem European business | ~₹36 cr, up ~37% from ₹26 cr |
| Ipca US products launched | 4 products launched; another 4–5 expected in FY26 |
| Ipca US products under development | ~15–16 products |